Lucanthone (Lucanthonum) is an inhibitor of Apurinic endonuclease-1 (APE-1).

Lucanthone是一种新型的自噬抑制剂，能够诱导通过cathepsin D介导的细胞凋亡。通过MTT测定法评估Lucanthone的抗癌活性，发现Lucanthone可显著降低七种乳腺癌细胞系的细胞活性。与Chloroquine（CQ）相比，Lucanthone在降低乳腺癌细胞活性方面显著更为有效，平均IC50值为7.2μM，而CQ为66μM。在两个代表性细胞系（MDA-MB-231和BT-20）中，通过ATPlite测定和trypan蓝排除实验，得到了一致的细胞活性测量结果[2]。

Cell viability is assessed by MTT assay. Cells are seeded into 96-well microculture plates at 10,000 cells per well and allowed to attach for 24 h. Cells are then treated with Lucanthone (0, 0.5, 1, 5, 10, 20 and 40 μM), Chloroquine, Vorinostat, or combinations for 72 h. Following drug treatment, MTT is added and cell viability is quantified using a BioTek microplate reader. Effects on cell viability are also determined by measuring ATP levels using the ATPlite assay system and by trypan blue exclusion. Pro-apoptotic effects following in vitro drug exposure are quantified by propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS) analysis of sub-G0/G1 DNA content[2]